NEW
YORK, June 10, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Biogen
Inc. (NASDAQ: BIIB).
Shareholders who purchased shares of BIIB during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=83256&from=4
CLASS PERIOD: February 3,
2022 to February 13, 2024
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i) Biogen
had overstated its efforts to enhance its transparency, corporate
governance, and compliance controls and procedures, as well as the
efficacy of those controls and procedures; (ii) accordingly, Biogen
maintained inadequate compliance controls and procedures in
connection with its business operations in foreign countries; (iii)
Biogen and/or its employees were engaged in unlawful or otherwise
improper conduct in several foreign countries; (iv) the foregoing
subjected the Company to a heightened risk of governmental and/or
regulatory scrutiny and enforcement action, as well as significant
legal, financial, and reputational harm; (v) Biogen overstated the
strength of its Alzheimer's disease related product portfolio,
including the its joint efforts and success with pharmaceutical
company, Eisai, in launching and providing access to Leqembi; (vi)
Biogen also downplayed the negative impact that the Reata
Acquisition would have on its FY 2023 non-GAAP diluted EPS; (vii)
all the foregoing were likely to have a significant negative impact
on Biogen's 2023 results; and (viii) as a result, the Company's
public statements were materially false and misleading at all
relevant times.
DEADLINE: July 22, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=83256&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of BIIB during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is July 22, 2024. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lost-money-on-biogen-incbiib-join-class-action-suit-seeking-recovery--contact-the-gross-law-firm-302167530.html
SOURCE The Gross Law Firm